SAB Biotherapeutics Inc. has announced positive confirmatory results from a Phase 1 clinical trial of SAB-142, a human anti-thymocyte immunoglobulin (hATG) therapy being developed for the treatment of stage 3 type 1 diabetes (T1D). The Phase 1 study, which included healthy volunteers and T1D patients, met its primary objectives by establishing a favorable safety profile and demonstrating low or no immunogenicity, with no cases of serum sickness reported. Based on these results, SAB-142 has advanced to the registrational Phase 2b SAFEGUARD trial, which is currently underway and recruiting adult and pediatric patients with new-onset, stage 3 T1D at multiple sites worldwide. The company plans to dose the first patient by the end of the year. The Phase 1 results have already been presented.